PrEP Twice a Year? Science Finally Understands That Sluts Are Busy

Let's be honest: taking one pill every day sounds simple until you remember that human beings are chaotic. We travel, work twelve-hour shifts, stay over at somebody's house, lose prescriptions, and occasionally wake up unsure where our underwear went. None of that means we don't deserve excellent HIV prevention.

The PURPOSE 2 study tested lenacapavir, an injectable form of PrEP given only twice a year, among cisgender gay and bisexual men and gender-diverse people. It prevented significantly more HIV infections than the estimated background rate, with only two infections among more than 2,100 participants receiving lenacapavir. The study included people from several countries and intentionally recruited populations often underserved by existing PrEP programs.

The FDA approved lenacapavir for HIV prevention under the brand name Yeztugo in June 2025, based on the PURPOSE 1 and PURPOSE 2 trials, and U.S. clinical guidance now lists it as an option for eligible adults and adolescents.

My opinion? This is huge. Sexual-health programs have spent years acting as though forgetting a pill is a character flaw. It is not. Prevention needs to fit people's lives — not demand that people rearrange their lives around prevention.

Twice-yearly PrEP will not replace every other option. Some people love daily pills. Others prefer injections every two months. The sexy part is having choices.